Oxazepam (Oxazepam Tablets) Side Effects, Interactions, Warning
Home A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z

Oxazepam (Oxazepam Tablets) Side Effects, Interactions, Warning


Polemeds.orgOxazepam
7.23.2017 | Nicholas Babcock
Oxazepam
Oxazepam (Oxazepam Tablets) Side Effects, Interactions, Warning

In more serious cases, and especially when other drugs or alcohol were ingested, symptoms may include ataxia, hypotonia, hypotension, hypnotic state, stage one (1) to three (3) coma, and very rarely, death. Overdosage of benzodiazepines is usually manifested by varying degrees of central nervous system depression ranging from drowsiness to coma. In mild cases, symptoms include drowsiness, mental confusion and lethargy.

Absolute dosage for pediatric patients 6 to 12 years of age is not established. This product is not indicated in pediatric patients under 6 years of age.

Consequently, after extended therapy, abrupt discontinuation should generally be avoided and a gradual dosage-tapering schedule followed. Withdrawal symptoms, similar in character to those noted with barbiturates and alcohol (convulsions, tremor, abdominal and muscle cramps, vomiting, and sweating ), have occurred following abrupt discontinuance of oxazepam. Generally milder withdrawal symptoms (e.g., dysphoria and insomnia ) have been reported following abrupt discontinuance of benzodiazepines taken continuously at therapeutic levels for several months. Addiction-prone individuals (such as drug addicts or alcoholics) should be under careful surveillance when receiving oxazepam or other psychotropic agents because of the predisposition of such patients to habituation and dependence. The more severe withdrawal symptoms have usually been limited to those patients who received excessive doses over an extended period of time.

Periodic blood counts and liver-function tests are advisable. Although rare, leukopenia and hepatic dysfunction including Jaundice have been reported during therapy.

Patients should be warned that the effects of alcohol or other CNS-depressant drugs may be additive to those of Oxazepam, possibly requiring adjustment of dosage or elimination of such agents.

Anxiety associated with depression is also responsive to Oxazepam therapy.

Serax (oxazepam) is indicated for the management of anxiety disorders or for the short-term relief of the symptoms of anxiety. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic.

Withdrawal symptoms of the barbiturate type have occurred after the discontinuation of benzodiazepines (see Drug Abuse And Dependence ).

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.

In the management of overdosage with any drug, it should be borne in mind that multiple agents may have been taken.

Oxazepam Capsules are classified by the Drug Enforcement Administration as a schedule IV controlled substance.

Oxazepam is not indicated in psychoses. History of previous hypersensitivity reaction to oxazepam.

A case of an extensive fixed drug eruption also has been reported. Other side effects occurring during oxazepam therapy include rare instances of nausea, lethargy, edema, slurred speech, tremor, altered libido, and minor diffuse skin rashes—morbilliform, urticarial, and maculopapular. Such side effects have been Infrequent and are generally controlled with reduction of dosage.

Distributed by: American Health Packaging, Columbus, OH 43217. Revised: Apr 2014.

This product has been found particularly useful in the management of anxiety, tension, agitation, and irritability in older patients.

Serax (oxazepam) Capsules and Tablets.

In the management of overdosage with any drug, it should be borne in mind that multiple agents may have been taken.

Oxazepam capsules are available as follows:

Call your doctor at once if you have any of these serious side effects:

The complete flumazenil package insert including CONTRAINDICATIONS, WARNINGS, and PRECAUTIONS should be consulted prior to use. The prescriber should be aware of a risk of seizure in association with flumazenil treatment, particularly in long-term benzodiazepine users and in cyclic antidepressant overdose. The benzodiazepine antagonist flumazenil may be used in hospitalized patients as an adjunct to, not as a substitute for, proper management of benzodiazepine overdose.

10 mg—D&C Red 22, D&C Red 28, and FD&C Blue 1; 15 mg—FD&C Yellow 6; 30 mg—D&C Red 28 and FD&C Blue 1.

The physician should periodically reassess the usefulness of the drug for the individual patient. The effectiveness of Serax (oxazepam) in long-term use, that is, more than 4 months, has not been assessed by systematic clinical studies.

This product is not indicated in pediatric patients under 6 years of age. Absolute dosage for pediatric patients 6 to 12 years of age is not established.

Manufactured for Fauldino Laboratories Inc. Wyeth Laboratories Inc., A Wyeth-Ayerst Company Philadelphia PA 19101. Revision June 2000. By. Raleigh, NC 27608.

Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. Oxazepam is indicated for the management of anxiety disorders or for the short-term relief of the symptoms of anxiety.

i.e., excitement, stimulation of affect, have been reported in psychiatric patients; these reactions may be secondary to relief of anxiety and usually appear in the first two weeks of therapy. Transient, mild drowsiness is commonly seen In the first few days of therapy. Mild paradoxical reactions. The necessity for discontinuation of therapy due to undesirable effects has been rare. In few instances, dizziness, vertigo, headache, and rarely syncope have occurred either alone or together with drowsiness. If it persists, the dosage should be reduced.

The more severe withdrawal symptoms have usually been limited to those patients who received excessive doses over an extended period of time. Generally milder withdrawal symptoms (e.g., dysphoria and insomnia) have been reported following abrupt discontinuance of benzodiazepines taken continuously at therapeutic levels for several months. Withdrawal symptoms, similar in character to those noted with barbiturates and alcohol (convulsions, tremor, abdominal and muscle cramps, vomiting, and sweating), have occurred following abrupt discontinuance of oxazepam. Addiction- prone individuals (such as drug addicts or alcoholics) should be under careful surveillance when receiving oxazepam or other psychotropic agents because of the predisposition of such patients to habituation and dependence. Consequently, after extended therapy, abrupt discontinuation should generally be avoided and a gradual dosage-tapering schedule followed.

A therapeutic agent providing versatility and flexibility in control of common emotional disturbances, this product exerts prompt action in a wide variety of disorders associated with anxiety, tension, agitation, and irritability, and anxiety associated with depression. Serax (oxazepam) is the first of a chemical series of compounds known as the 3-hydroxybenzodiazepinones. In tolerance and toxicity studies on several animal species, this product reveals significantly greater safety factors than related compounds (chlordiazepoxide and diazepam) and manifests a wide separation of effective doses and doses inducing side effects.

Alcoholics with acute tremulousness, inebriation, or with anxiety associated with alcohol withdrawal are responsive to therapy.

Periodic blood counts and liver-function tests are advisable. Although rare, leukopenia and hepatic dysfunction including jaundice have been reported during therapy.

As with other CNS-acting drugs, patients should be cautioned against driving automobiles or operating dangerous machinery until it is known that they do not become drowsy or dizzy on oxazepam therapy.

A case of an extensive fixed drug eruption also has been reported. Such side effects have been infrequent and are generally controlled with reduction of dosage. Other side effects occurring during oxazepam therapy include rare instances of nausea, lethargy, edema, slurred speech, tremor, altered libido, and minor diffuse skin rashes — morbilliform, urticarial, and maculopapular.

Because use of these drugs is rarely a matter of urgency, their use during this period should almost always be avoided. The possibility that a woman of childbearing potential may be pregnant at the time of Institution Of therapy should be considered. Serax (oxazepam), a benzodiazepine derivative, has not been studied adequay to determine whether It, too, may be associated with an increased risk of fetal abnormality. Patients should be advised that if they become pregnant during therapy or intend to become pregnant they should communicate with their physician about the desirability of discontinuing the drug. An increased risk of congenital malformations associated with the use of minor tranquilizers (chlordiazepoxide, diazepam, and meprobamate) during the first trimester of pregnancy has been suggested in several studies.

10 mg, NDC, white and pink capsule marked "SERAX (oxazepam) ", "10*. and "327", in bottles of 100 capsules.

Store at room temperature, approximay 25° C (77* F). Dispense in tight container. Keep tightly closed. Reference.

Patients should be advised that if they become pregnant during therapy or intend to become pregnant they should communicate with their physician about the desirability of discontinuing the drug. The possibility that a woman of childbearing potential may be pregnant at the time of institution of therapy should be considered. An increased risk of congenital malformations associated with the use of minor tranquilizers (chlordiazepoxide, diazepam, and meprobamate) during the first trimes ter of pregnancy has been suggested in several studies. Because use of these drugs is rarely a matter of urgency, their use during this period should almost always be avoided. Oxazepam, a benzodiazepine derivative, has not been studied adequay to determine whether it, too, may be associated with an increased risk of fetal abnormality.

If it persists, the dosage should be reduced. The necessity for discontinuation of therapy due to undesirable effects has been rare. Mild paradoxical reactions, i.e., excitement, stimulation of affect, have been reported in psychiatric patients; these reactions may be secondary to relief of anxiety and usually appear in the first two weeks of therapy. Transient, mild drowsiness is commonly seen in the first few days of therapy. In few instances, dizziness, vertigo, headache, and rarely syncope have occurred either alone or together with drowsiness.

Absolute dosage for pediatric patients 6 to 12 years of age is not established. Safety and effectiveness in pediatric patients under 6 years of age have not been established.

The effectiveness of Oxazepam in long-term use, that is, more than 4 months, has not been assessed by systematic clinical studies. The physician should periodically reassess the usefulness of the drug for the individual patient.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.

Ataxia with oxazepam has been reported in rare instances and does not appear to be specifically related to dose or age.

Less serious side effects may.

Each dosage strength also contains the following:. The inactive ingredients present are FD&C Red 40, gelatin, lactose, titanium dioxide, and other ingredients. Serax capsules contain 10 mg, 15 mg, or 30 mg oxazepam.

home drugs a-z list side effects drug center oxazepam (oxazepam tablets) drug.

Although the following side reactions have not as yet been reported with oxazepam, they have occurred with related compounds (chlordiazepoxide and diazepam): paradoxical excitation with severe rage reactions, hallucinations, menstrual irregularities, change in EEG pattern, blood dyscrasias including agranulocytosis, blurred vision, diplopia, incontinence, stupor, disorientation, fever, and euphoria.

30 mg, NDC, white and maroon capsule marked "SERAX (oxazepam) ", "30". and "329", in bottles of 100 capsules.

Induced vomiting and/or gastric lavage should be undertaken, followed by general supportive care, monitoring of vital signs, and close observation of the patient. Hypotension, though unlikely, usually may be controlled with norepinephrine bitartrate injection. The value of dialysis has not been adequay determined for oxazepam.

Patients should be warned that the effects of alcohol or other CNS-depressant drugs may be additive to those of Serax (oxazepam), possibly requiring adjustment of dosage or elimination of such agents.

Greater sensitivity of some older individuals to the effects of Serax (oxazepam) (e.g., sedation, hypotension, paradoxical excitation) cannot be ruled out (see PRECAUTIONS, General ; see ADVERSE REACTIONS ). In general, dose selection for Serax (oxazepam) for elderly patients should be cautious, usually starting at the lower end of the dosing range (See DOSAGE AND ADMINISTRATION ). Clinical circumstances, some of which may be more common in the elderly, such as hepatic or renal impairment, should be considered.

As with other CNS-acting drugs, patients should be cautioned against driving automobiles or operating dangerous machinery until it is known that they do not become drowsy or dizzy on oxazepam therapy.

Serax (oxazepam) Capsules and Tablets are available In the following dosage strengths:

Age (<80 years old) does not appear to have a clinically significant effect on oxazepam kinetics (see CLINICAL PHARMACOLOGY ). Clinical studies of oxazepam were not adequate to determine whether subjects aged 65 and over respond differently than younger subjects.

Clinical studies of Serax (oxazepam) were not adequate to determine whether subjects aged 65 and over respond differently than younger subjects. Age (< 80 years old) does not appear to have a clinically significant effect on oxazepam kinetics (see CLINICAL PHARMACOLOGY ).

Ataxia with oxazepam has been reported in rare instances and does not appear to be specifically related to dose or age.

15 mg, NDC, yellow, five-sided, flat-faced, beveled edge tablet with a raised "S* on one side and "SERAX (oxazepam) " and "15" on the other side, in bottles of 100 tablets.

Although the overall incidence of FD&C Yellow 5 (tartrazine) sensitivity in the general population is low, it is frequently seen in patients who also have aspirin hypersensitivity. Serax (oxazepam) 15 mg tablets, but none of the other available dosage forms of this product, contain FD&C Yellow 5 (tartrazine) which may cause allergic-type reactions (including bronchial asthma ) in certain susceptible individuals.

Absolute dosage for pediatric patients 6 to 12 years of age is not established. Safety and effectiveness in pediatric patients under 6 years of age have not been established.

Although the following side reactions have not as yet been reported with oxazepam, they have occurred with related compounds (chlordiazepoxide and diazepam): paradoxical excitation with severe rage reactions, hallucinations, menstrual irregularities, change In EEG pattern, blood dyscrasias including agranulocytosis, blurred vision, diplopia, incontinence, stupor, disorientation, fever, and euphoria.

15 mg, NDC, white and red capsule marked "SERAX (oxazepam) ", "15", and "328", in bottles of 100 capsules.

This product has been found particularly useful in the management of anxiety, tension, agitation, and irritability in older patients. Anxiety associated with depression is also responsive to Serax (oxazepam) therapy.

Although hypotension has occurred only rarely, oxazepam should be administered with caution to patients in whom a drop in blood pressure might lead to cardiac complications. This is particularly true in the elderly patient.

Alcoholics with acute tremulousness, inebriation, or with anxiety, associated with alcohol withdrawal are responsive to therapy.

No Information Provided. Transient amnesia or memory impairment has been reported in association with the use of benzodiazepines.

Transient amnesia or memory impairment has been reported in association with the use of benzodiazepines. No information provided.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.

Because of the flexibility of this product and the range of emotional disturbances responsive to it, dosage should be individualized for maximum beneficial effects.

Initial dosage: 10 mg, 3 times daily. Alcoholics with acute inebriation, tremulousness, or anxiety on withdrawal. If necessary, increase cautiously to 15 mg, 3 or 4 times daily. 15 to 30 mg, 3 or 4 times daily Older patients with anxiety, tension, irritability, and agitation. 15 to 30 mg, 3 or 4 times daily. Mild-to-moderate anxiety, with associated tension, irritability, agitation, or related symptoms of functional origin or secondary to organic disease. 10 to 15 mg, 3 or 4 times daily Severe anxiety syndromes, agitation, or anxiety associated with depression.

Serax tablets contain 15 mg oxazepam. Serax (oxazepam) is 7-chloro-1,3-dihydro-3-hydroxy-5-phenyl-2H-1,4-benzodi-azepin-2-one. The inactive ingredients present are FD&C Yellow 5, lactose, magnesium stearate, methylcellulose and polacrilin potassium. A white crystalline powder with a molecular weight of 286.7, its structural formula is as follows:.

In general, dose selection for oxazepam for elderly patients should be cautious, usually starting at the lower end of the dosing range (see DOSAGE AND ADMINISTRATION ). Clinical circumstances, some of which may be more common in the elderly, such as hepatic or renal impairment, should be considered. Greater sensitivity of some older individuals to the effects of oxazepam (e.g., sedation, hypotension, paradoxical excitation) cannot be ruled out (see PRECAUTIONS, General ; ADVERSE REACTIONS ).

Find Lowest Prices on.

Because of the flexibility of this product and the range of emotional disturbances responsive to it, dosage should be individualized for maximum beneficial effects.

This is particularly true in the elderly patient. Although hypotension has occurred only rarely, oxazepam should be administered with caution to patients in whom a drop in blood pressure might lead to cardiac complications.

Commun. 8:481-488,1974. Chem. Res. FOX, KA; LAHCEN, R.8.: Liver-cell Adenomas and Poliosis Hepatis In Mice Associated with Oxazepam. Pathol. Pharmacol. 1.

15 to 30 mg, 3 or 4 times daily*. Mild-to-moderate anxiety, with associated tension, irritability, agitation, or related symptoms of functional origin or secondary to organic disease. 15 to 30 mg, 3 or 4 times daily Older patients with anxiety, tension, irritability, and agitation. Alcoholics with acute inebriation, tremulousness, or anxiety on withdrawal. Initial dosage: 10 mg, 3 times daily, if necessary, increase cautiously to 15 mg, 3 or 4 times daily. 10 to 15 mg, 3 or 4 times daily Severe anxiety syndromes, agitation, or anxiety associated with depression.

In mild cases, symptoms include drowsiness, mental confusion and lethargy. In more serious cases, and especially when other drugs or alcohol were Ingested, symptoms may include ataxia, hypotonia, hypotension, hypnotic state, stage one (1) to three (3) coma, and very rarely, death. Overdosage of benzodiazepines is usually manifested by varying degrees of central nervous system depression ranging from drowsiness to coma.

Oxazepam